Knihinicki R D, Day R O, Graham G G, Williams K M
Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Darlinghurst, Australia.
Chirality. 1990;2(3):134-40. doi: 10.1002/chir.530020303.
(R)-2-Arylpropionates are often inverted to the pharmacologically active S-enantiomers in vivo, although there is significant interspecies variability in inversion. In order to provide a basis for determining the biochemical consequences of this unique process using rats as a model, it was important to establish the pharmacokinetic disposition of the enantiomers of ibuprofen, a drug well inverted in man and flurbiprofen, a drug apparently poorly inverted in man. Rats were dosed i.v. with a single dose of (R)- or (S)-ibuprofen (20 mg/kg), (R,S)-ibuprofen (40 mg/kg), (R)- or (S)-flurbiprofen (10 mg/kg), or (R,S)-flurbiprofen (20 mg/kg). Each treatment group consisted of six animals. Serial blood samples were withdrawn over a period of 6 h for ibuprofen and 10 h for flurbiprofen. These drugs were assayed in plasma by a stereospecific HPLC assay. The pharmacokinetics of the ibuprofen and flurbiprofen enantiomers were evaluated using a two-compartment open model with conversion of the R- to S-enantiomers in the central compartment. There was 50 +/- 4% inversion of (R)-ibuprofen, a figure similar to that observed in man and (R)-ibuprofen had a higher clearance (12.6 +/- 1.3 ml/min/kg) than (S)-ibuprofen (7.7 +/- 0.7 ml/min/kg; P less than 0.01). The clearance of (R)-flurbiprofen after racemate (2.3 +/- 0.1 ml/min/kg) was higher than its clearance when administered alone (1.7 +/- 0.2 ml/min/kg; P less than 0.01), indicating a pharmacokinetic interaction between the enantiomers (most probably at plasma protein binding sites). A corresponding difference was not observed for ibuprofen. There was a small amount of inversion of (R)-flurbiprofen as determined by area analysis (4.5 +/- 1.6%).(ABSTRACT TRUNCATED AT 250 WORDS)
(R)-2-芳基丙酸酯在体内常转化为具有药理活性的S-对映体,尽管转化过程存在显著的种间差异。为了以大鼠为模型为确定这一独特过程的生化后果提供依据,有必要确定布洛芬(一种在人体内转化良好的药物)和氟比洛芬(一种在人体内明显转化较差的药物)对映体的药代动力学特征。给大鼠静脉注射单剂量的(R)-或(S)-布洛芬(20mg/kg)、(R,S)-布洛芬(40mg/kg)、(R)-或(S)-氟比洛芬(10mg/kg)或(R,S)-氟比洛芬(20mg/kg)。每个治疗组由6只动物组成。对布洛芬采集6小时、对氟比洛芬采集10小时的系列血样。通过立体特异性高效液相色谱法测定血浆中的这些药物。使用二室开放模型评估布洛芬和氟比洛芬对映体的药代动力学,其中中央室存在R-对映体向S-对映体的转化。(R)-布洛芬有50±4%的转化,这一数字与在人体中观察到的相似,且(R)-布洛芬的清除率(12.6±1.3ml/min/kg)高于(S)-布洛芬(7.7±0.7ml/min/kg;P<0.01)。外消旋体给药后(R)-氟比洛芬的清除率(2.3±0.1ml/min/kg)高于单独给药时的清除率(1.7±0.2ml/min/kg;P<0.01),表明对映体之间存在药代动力学相互作用(很可能发生在血浆蛋白结合位点)。布洛芬未观察到相应差异。通过面积分析确定(R)-氟比洛芬有少量转化(4.5±1.6%)。(摘要截短于250字)